The Journal of Allergy and Clinical Immunology
Volume 118, Issue 2 , Pages 434-440 , August 2006

Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis

  • Ronald Dahl, MD

      Affiliations

    • From the Department of Respiratory Diseases, Aarhus University Hospital
    • ,
  • Alexander Kapp, MD

      Affiliations

    • Department of Dermatology and Allergology, Hannover Medical University
    • ,
  • Giselda Colombo, MD

      Affiliations

    • Ospedale San Raffaele del Monte Tabor, Medicina Interna Allergologia, Milan
    • ,
  • Jan G.R. de Monchy, MD

      Affiliations

    • Division of Allergology, University of Groningen
    • ,
  • Sabina Rak, MD

      Affiliations

    • Section of Allergy, Sahlgrenska University Hospital, Gothenburg
    • ,
  • Waltraud Emminger, MD

      Affiliations

    • Allergie-Ambulatorium Rennweg, Vienna
    • ,
  • Montserrat Fernández Rivas, MD

      Affiliations

    • Fundación Hospital Alcorcón, Madrid
    • ,
  • Mette Ribel, MSc

      Affiliations

    • Group Clinical Development, ALK-Abelló A/S, Hørsholm
    • ,
  • Stephen R. Durham, MD

      Affiliations

    • Section of Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College and Royal Brompton Hospital, London
    • Corresponding Author InformationReprint requests: Stephen R. Durham, MD, MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, Head, Section of Allergy and Clinical Immunology, National Heart and Lung Institute, Royal Brompton Hospital, Guy Scadding Building, Royal Brompton Campus, Dovehouse Street, SW3 6LY London, United Kingdom.

Received 20 February 2006 ,Revised 2 May 2006 ,Accepted 4 May 2006.

References 

  1. Dahl R, Andersen PS, Chivato T, Valovirta E, de Monchy J. National prevalence of respiratory allergic disorders. Respir Med. 2004;98:398–403
  2. White P, Smith H, Baker N, Davis W, Frew A. Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?. Clin Exp Allergy. 1998;28:266–270
  3. Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol. 2001;107:87–93
  4. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ. 1991;302:265–269
  5. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341:468–475
  6. Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children: a 14-year study. Pediatrics. 1968;42:793–802
  7. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109:251–256
  8. Passalacqua G, Baena-Cagnani CE, Berardi M, Canonica GW. Oral and sublingual immunotherapy in paediatric patients. Curr Opin Allergy Clin Immunol. 2003;3:139–145
  9. Roches AD, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract, VI: specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol. 1997;99:450–453
  10. Passalacqua G, Lombardi C, Canonica GW. Sublingual immunotherapy: an update. Curr Opin Allergy Clin Immunol. 2004;4:31–36
  11. Wilson DR, Torres LM, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy. 2005;60:4–12
  12. Malling HJ. Is sublingual immunotherapy clinically effective?. Curr Opin Allergy Clin Immunol. 2002;2:523–531
  13. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy. 2006;61:181–184
  14. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual once-daily grass-pollen immunotherapy: a randomised controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117:802–809
  15. Declaration of Helsinki . Recommendations guiding physicians in biomedical research involving human subjects. Republic of South Africa: World Medical Association; 1996;
  16. Frew A, Powell RJ, Corrigan CJ, Durham S. Efficacy and safety of specific immunotherapy with SQ-allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117:319–325
  17. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med. 2004;116:338–344
  18. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy. 2006;61:185–190
  19. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004;113:1025–1034
  20. Robinson DS, Larche M, Durham SR. Tregs and allergic disease. J Clin Invest. 2004;114:1389–1397
  21. Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy. 1995;50:405–413
  22. Lima MT, Wilson D, Pitkin L, Roberts A, Nouri-Aria KT, Jacobson M, et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy. 2002;32:507–514

 Supported by ALK-Abelló A/S, Denmark.Disclosure of potential conflict of interest: S. R. Durham has consultant arrangements with, has received grant support from, and is on the speakers' bureau for ALK-Abelló. R. Dahl has consultant arrangements with Altana, GlaxoSmithKline, Boehringer Ingelheim, Novartis, and Fertin, and has received grant support from Altana, GlaxoSmithKline, Boehringer Ingelheim, Novartis, AstraZeneca, ALK-Abelló, Roche, and Pfizer. A. Kapp has consultant arrangements with DPC, has received grant support from Novartis, Astellas, UCB, ALK-Abelló, and DPC, and is on the speakers' bureau for Nofartis, Astellas, UCB, and ALK-Abelló. S. Rak has received grant support from the Swedish Asthma and Allergy Association. M. Fernandez-Rivas has received grant support from the European Commission and the Instituto de Salud Carlos III of the Spanish Ministry of Health. M. Ribel is employed by ALK-Abelló A/S. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(06)01135-3

doi: 10.1016/j.jaci.2006.05.003

The Journal of Allergy and Clinical Immunology
Volume 118, Issue 2 , Pages 434-440 , August 2006

Article Tools

* Image Usage & Resolution